On Wednesday, Shares of Gastar Exploration Inc (NYSEMKT:GST), gained 2.76% to $3.35.
Gastar Exploration, declared that the closing of the formerly declared sale of certain non-core assets in Oklahoma to an unrevealed private third-party has been extended to July 6, 2015, with the same property sale effective date of April 1, 2015. The buyer has made a deposit payment of $6.6 million towards the sales price, which remains unchanged at $46.2 million. Except under certain limited circumstances, the $6.6 million deposit is non-refundable.
Gastar Exploration Inc., an independent energy company, engages in the exploration, development, and production of oil, condensate, natural gas, and natural gas liquids in the United States.
Shares of Lam Research Corporation (NASDAQ:LRCX), declined -0.68% to $83.21, during its last trading session.
Lam Research Corporation, declared it will host an investor and analyst meeting in San Francisco on Tuesday, July 14, 2015, from 9:00 a.m. to 11:00 a.m. Pacific Time at the Park Central Hotel (formerly known as the Westin San Francisco Market Street). The meeting, which coincides with SEMICON West 2015, will serve as a general update for investors and analysts on Lam’s strategy and operations.
Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing systems used in the fabrication of integrated circuits.
At the end of Wednesday’s trade, Shares of The Medicines Company (NASDAQ:MDCO), lost -0.97% to $29.62.
The Medicines Company, declared the approval of KENGREAL (cangrelor) by the U.S. Food and Drug Administration (FDA) as an adjunctive therapy to percutaneous coronary intervention (PCI) for reducing periprocedural thrombotic events in patients who have not been treated with a P2Y12 inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor (GPI).
The Medicines Company anticipates KENGREAL to be accessible in the U.S. in July.
KENGREAL is the first and only intravenous, reversible P2Y12 platelet inhibitor with an immediate onset of action for patients undergoing PCI that, in clinical trials, has been shown to reduce the risk of periprocedural thrombotic events, counting myocardial infarction, stent thrombosis, and repeat coronary revascularization.
The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention.
Finally, KLA-Tencor Corp (NASDAQ:KLAC), ended its last trade with -0.12% loss, and closed at $57.21.
KLA-Tencor Corp, declared that it will host its annual analyst briefing at SEMICON West at the W Hotel on Tuesday, July 14, 2015, with a live webcast starting at 12:30 p.m. PDT. The agenda comprises:
- 12:00-12:30 p.m.: Registration
- 12:30-2:00 p.m.: Presentation with Q&A by President and CEO Rick Wallace and CFO Bren Higgins
KLA-Tencor Corporation designs, manufactures, and markets process control and yield administration solutions worldwide. It provides chip manufacturing products, counting front-end defect inspection, back-end defect inspection, defect review, metrology, and in-situ process monitoring products, in addition to lithography modeling software; wafer manufacturing products comprising surface and defect inspection, wafer geometry and nanotopography metrology, and data administration; and reticle manufacturing products, such as defect inspection and pattern placement metrology products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
